Cargando…
Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
BACKGROUND: Human soluble recombinant thrombomodulin (TM alfa), a treatment for septic Disseminated intravascular coagulation (DIC), is recommended for patients with severe renal dysfunction in reduced doses. However, no studies have examined yet how dose reduction affects clinical efficacy. In this...
Autores principales: | Nishita, Yoshihiro, Taga, Masatoshi, Sakurai, Masaru, Iinuma, Yoshitsugu, Masauji, Togen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743769/ https://www.ncbi.nlm.nih.gov/pubmed/36503588 http://dx.doi.org/10.1186/s40780-022-00264-9 |
Ejemplares similares
-
Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation
por: Ikezoe, Takayuki
Publicado: (2015) -
Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013) -
Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010) -
Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015) -
Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments
por: Hayakawa, Mineji
Publicado: (2017)